21 June 2013Americas

Federal Circuit holds Novo Nordisk patent invalid

The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 May 2026   A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.
Americas
26 May 2026   Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.
Americas
26 May 2026   Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.